The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1531219
This article is part of the Research Topic Immunotherapy Resistance and Advancing Adaptive Cell Therapeutics View all 5 articles
Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis
Provisionally accepted- The People's Hospital of Leshan, Leshan, China
Backgroud: Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a metaanalysis to evaluate its prognostic value in human cancers. Methods: PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis.The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression-free survival (PFS) and disease-free survival(DFS).Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage. Results: A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI:1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg's and Egger's test demostrated that no obvious publication bias was exist. Conclusions:High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
Keywords: PD-1+CD8+ T cells, overall survival, Progression-free survival, Disease-Free Survival, Cancer
Received: 20 Nov 2024; Accepted: 20 Dec 2024.
Copyright: © 2024 Wan, cui, yang, liao, chen, li, xiang, xiang and yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhi yong Wan, The People's Hospital of Leshan, Leshan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.